NewAmsterdam Pharma announced additional results from its Phase 3 BROOKLYN clinical trial, evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia (HeFH). The trial met its primary endpoint, demonstrating a statistically significant mean reduction in LDL-C versus placebo of 36.3% at day 84, which was sustained at 41.5% at day 365.
Beyond LDL-C, obicetrapib also achieved a mean reduction in lipoprotein(a) (Lp(a)) versus placebo of 45.9% at day 84 and 54.3% at day 365. Furthermore, a mean reduction in total LDL-P of 52.5% at day 180 was observed, including a 102.4% reduction in small LDL-P, indicating a broad impact on atherogenic lipids.
The safety profile of obicetrapib was observed to be comparable to placebo, with no increase in blood pressure and a lower treatment discontinuation rate in the obicetrapib arm (7.6%) compared to placebo (14.4%). These results underscore obicetrapib's potential as a safe and effective oral therapy for HeFH patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.